Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069855 | 0.97 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11CCNT1 | |
| SCHEMBL2080167 | 0.92 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11CCNT1 | |
| SCHEMBL2079157 | 0.91 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11CCNT1 | |
| SCHEMBL2079373 | 0.84 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11CCNT1 | |
| SCHEMBL4255507 | 0.84 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11ATR | |
| SCHEMBL2079128 | 0.84 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11ATR | |
| SCHEMBL2080009 | 0.82 | MAPK14 (0.85) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2080714 | 0.80 | CCNT1 (0.51) | MAPK14CCNT1 | |
| SCHEMBL2078868 | 0.79 | ATR (0.56) | MAPK14MAPK13MAPK12MAPK11ATR | |
| SCHEMBL2078103 | 0.78 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906530-B2 | 1,7-naphthyridine derivatives as p38 MAP kinase inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-03-15 | — | — | US | claimed |
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-09 | — | — | US | claimed |
| EP-2049537-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | Laboratorios Almirall, S.A. (ES) | 2009-04-22 | — | — | EP | claimed |
| WO-2008017461-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-02-14 | — | — | WO | claimed |
| US-7906530-B2 | 1,7-naphthyridine derivatives as p38 MAP kinase inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-03-15 | — | — | US | disclosed |
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-09 | — | — | US | disclosed |
| EP-2049537-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | Laboratorios Almirall, S.A. (ES) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008017461-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | MAPK1, MAPK7, MAPKAPK2 | MAPK14 23/4885MAPK13 38/4885MAPK12 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.